FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Articles|June 15, 2021
COVID-19 Updates: US Vaccinations and Global Cases and Deaths as of June 15, 2021
Author(s)Sydney Jennings
US COVID-19 mortalities have surpassed 600 000. We summarize more of today's data from the Johns Hopkins COVID-19 interactive map and the CDC.
Advertisement
How many people in the US have been vaccinated against COVID-19?
According to the US
• 52.6% of total US population has received at least 1 dose
• 43.9% of total US population is fully vaccinated
• 43.9% of total US population is fully vaccinated
The 5 states with the highest percentage of population fully vaccinated are:
1. Vermont: 62.7%
2. Maine: 58.7%
3. Massachusetts: 58.3%
4. Connecticut: 57.6%
5. Rhode Island: 55.7%
2. Maine: 58.7%
3. Massachusetts: 58.3%
4. Connecticut: 57.6%
5. Rhode Island: 55.7%
How many cases of COVID-19 have been confirmed in the US?
According to the
• 33 478 513 confirmed cases
• 600 039 deaths
• 600 039 deaths
The 5 states with the highest total confirmed cases are:
1. California: 3 803 374
2. Texas: 2 978 357
3. Florida: 2 344 321
4. New York: 2 109 677
5. Illinois: 1 387 679
2. Texas: 2 978 357
3. Florida: 2 344 321
4. New York: 2 109 677
5. Illinois: 1 387 679
Deaths: California has the most deaths due to COVID-19 with 63 195 reported fatalities, followed by New York with 53 558, and Texas with 51 940.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 176 386 418 confirmed cases, 3 814 371 deaths, and 2 397 324 414 vaccine doses administered.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
5 FDA Decisions for Primary Care to Know from September 2026
3
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
4
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
5